#USA #New York #Proton Therapy #Lung Cancer #SBRT

A Major Advancement in Lung Cancer Treatment

In a groundbreaking study published in The Lancet, researchers at the New York Proton Center (NYPC) unveiled promising results that have the potential to reshape the treatment landscape for patients with early-stage, inoperable lung cancer. The recently concluded SWOG/NRG Oncology S1914 clinical trial demonstrated that precision radiation therapy, specifically stereotactic body radiation therapy (SBRT), achieved an impressive overall two-year survival rate of 82%. This discovery represents a significant leap forward when compared to historical outcomes.

Dr. Charles B. Simone II, Chief Medical Officer at NYPC, played a pivotal role in this research as a co-first author. According to Dr. Simone, the trial is a landmark in the field of radiation oncology, offering hope to patients who for years had limited treatment options. "This trial illustrates the remarkable capabilities of modern precision radiation therapy in extending survival for patients who cannot undergo surgical intervention," he stated.

The Study's Scope and Impact

Conducted across 146 institutions, the SWOG/NRG Oncology S1914 trial enrolled 417 patients between March 2020 and September 2024. This trial is recognized as the largest prospective study evaluating the efficacy of SBRT alone in this patient demographic. The results are particularly striking, given that conventional radiation methods for inoperable lung cancer previously yielded two-year survival rates below 40%.

Before the establishment of SBRT as a standard care option, trials such as RTOG 0236 reported only a 55.8% three-year survival rate. The S1914 trial’s successful achievement of an 82% survival rate highlights the effectiveness of SBRT and sets a new benchmark for expected treatment outcomes. The data collected from this multi-institutional trial underscores its broad applicability and reliability across diverse healthcare settings.

A Shift in Treatment Paradigms

One noteworthy finding from the S1914 trial was that adding the immunotherapy drug atezolizumab did not enhance the effectiveness of SBRT. In fact, the combination was associated with increased adverse effects, with 12% of patients experiencing grade 3 or higher complications compared to just 3% for those receiving SBRT alone. These results lead researchers to conclude that SBRT monotherapy should remain the standard of care for these patients going forward.

The trial's use of a rigorous, centralized radiation review process contributed to its success, ensuring consistent treatment quality across all participating sites. Dr. Simone emphasized the importance of this quality assurance in achieving the remarkable results seen in the study.

The Future of Cancer Care

As part of NYPC's mission to redefine cancer treatment, this trial marks a significant milestone in lung cancer care for medically inoperable patients. By showcasing the high survival rate associated with SBRT monotherapy, the study not only enhances treatment possibilities but also establishes a model for future research in radiation oncology.

Christopher Panczner, CEO of NYPC, highlighted the significance of these findings in the broader context of cancer treatment. He remarked, "At NYPC, our goal is to influence the course of cancer care globally, and this research does just that. We are proud to contribute to the growing body of evidence that guides clinical decisions for patients in need."

As the field of proton therapy continues to evolve, the NYPC remains committed to pioneering advancements in cancer treatment. The success of the S1914 trial underscores the potential for innovative therapies to change lives, providing new hope for patients battling inoperable lung cancer. It is a compelling reminder of the continuous need for rigorous scientific inquiry and collaboration in the fight against cancer.

For more details about this landmark study, please visit NY Proton Center.